Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 18, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Repurchased: 2,600,000 ordinary shares.
- Repurchase Price: 1,037.79 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.28% of total voting rights).
- Shares in Issue: 5,432,394,058 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,600,000 shares. Consequently, the total number of shares in issue remains 5,432,394,058, while the Treasury holding stands at 504,194,158 shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory compliance with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,432,394,058) for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the Treasury share count (504,194,158) and its impact on total voting rights (9.28%).
- Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or other periodic reports for revenue and earnings data.